Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious program, conolidine modulates alternate molecular targets. A Science Innovations study identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://fredq382oxe6.blogproducer.com/profile